Alan Ashworth – San Francisco, USA
One of the world’s preeminent cancer scientists, Alan Ashworth is a molecular biologist, noted for his work on genes involved in cancer susceptibility. He is currently the President of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, a multidisciplinary research and clinical care organization that is one of the largest cancer centres in the Western United States. He was previously CEO of the Institute of Cancer Research (ICR) in London. His major contribution to cancer research has been his work on genes involved in cancer risk and he was a central part of the team that in 1995 discovered the gene BRCA2, which is linked to a heightened risk of some types of cancer. A decade later, Ashworth identified a way to exploit genetic weaknesses in cancer cells, including mutated BRCA2, leading to a new approach to cancer therapy. In 2008, he was elected as a Fellow of the Royal Society (FRS).
Andrew Biankin – Glasgow, UK
Regius Professor of Surgery; Director, Wolfson Wohl Cancer Research Centre, University of Glasgow.
Markus Büchler – Heidelberg, Germany
Professor Markus W. Büchler is the executive director and professor of surgery at the department of surgery at Heidelberg University. He is an internationally respected expert in the field of surgery, especially in the field of pancreatic surgery. More than 2200 authored scientific manuscripts published by him focused on the molecular basis of GI cancer and pancreatic diseases as well as clinical surgical problems. He is a member of the Royal Colleges of Surgeons of England and Scotland among other societies. He has received multiple scientific awards and is a member of the editorial boards of many well-known scientific journals.
Pippa Corrie – Cambridge, UK
Dr Pippa Corrie trained in London, Oxford and Birmingham, before being appointed Consultant and Associate Lecturer in Medical Oncology at Cambridge University Hospitals NHS Foundation Trust in 1996. Her specialist interests are pancreatic cancer and melanoma. She is engaged in both development and delivery of clinical research nationally. She chairs the NCRI Skin Cancer Clinical Studies Group, is a member of the NCRI Pancreatic Cancer Subgroup and is Clinical Lead for the CRN:Eastern Cancer Division. She is Chief Investigator of the NIHR portfolio multicentre trials: SIEGE and AVAST-M.
Anna Dominiczak – Glasgow, UK
Professor Anna Dominiczak (OBE, MD, FRCP, FRSE, FMedSci) is Regius Professor of Medicine, Vice Principal and Head of College of Medical, Veterinary and Life Sciences at the University of Glasgow as well as honorary consultant physician and non-executive member of the NHS Greater Glasgow and Clyde Health Board. One of the world’s leading cardiovascular scientists and clinical academics, Prof Dominiczak’s major research interests are in hypertension, cardiovascular genomics and precision medicine and her total research income in the last three years totals more than £30 million. She has led a collaboration of four universities and four academic NHS Health Boards across Scotland to develop public/private partnership in Stratified Medicine with a current value of £20 million. Prof Dominiczak is a Fellow of the Royal College of Physicians, the Academy of Medical Sciences, the Royal Society of Edinburgh, the American Heart Association and the European Society of Cardiology. She has published over 350 peer reviewed papers in top journals and is an immediate past President of the European Society of Hypertension and Editor-in-Chief of Hypertension, the journal of American Heart Association. In 2005 she was awarded OBE for services to medicine
Jeff Evans – Glasgow, UK
Professor Jeff Evans is a Group Leader (Translational Cancer Therapeutics Laboratory) at the CR-UK Beatson Institute, Glasgow, Professor of Translational Cancer Research and Director of the Institute of Cancer Sciences, University of Glasgow, and Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre, Glasgow. He is also the Lead of the Glasgow Experimental Cancer Medicine Centre (ECMC). His research interests are in the pre-clinical and clinical development of novel anti-cancer agents, particularly in pancreatic cancer, including the inhibition of metastases in localised disease and in exploiting tumour biology for therapy in advanced disease.
Alex Ford – Pancreatic Cancer UK
Following a ten year career focusing mainly on fundraising and marketing in higher education and theatre, Alex was diagnosed with ovarian cancer at the age of 33. In light of this diagnosis she decided to change focus completely and has now been working in the cancer world for over fifteen years as Director of Fundraising and Marketing at Breast Cancer Care, CEO at The Eve Appeal and, for the last five years, CEO at Pancreatic Cancer UK.
Steven Gallinger – Toronto, Canada
Dr. Steven Gallinger is a clinician-scientist, and surgical oncologist with an interest in gastrointestinal cancer genetics. As a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Dr. Gallinger studies the genetics of both inherited and acquired molecular aspects of colorectal and pancreatic cancer. Dr. Gallinger’s lab was one of the first to demonstrate that a gene mutation known as K-ras is present in early colorectal cancer cells. Dr. Gallinger and his team have also determined the sequence of molecular genetic events in Familial Adenomatous Polyposis. This has placed his lab at the forefront in the field of GI cancer genetics, both in Canada and internationally. Dr. Gallinger also contributed to the international ARCTIC Genome Project that identified a gene variation associated with colorectal cancer–the first genetic predictor associated with common forms of colorectal cancer and a tool for future screening methods. Recently, his group also played a key role in an international team that identified four new genes for colorectal cancer. The study examined 38,710 genetic markers in 13,315 individuals from four countries. A total of 10 genes are now linked to colorectal cancer, and together these genes could predict up to a six-fold increase in the lifetime risk of developing this common disease. In addition, Dr. Gallinger is identifying and characterizing the early molecular events during the development of pancreatic cancer.
O James Garden – Glasgow, UK
Professor Garden’s postgraduate surgical training in Edinburgh, Glasgow and Paris from 1978 to 1988 included a year as Chef de Clinique in the unit of Professor Henri Bismuth in Hospital Paul Brousse, Paris to train in hepatobiliary and liver transplant surgery. His election as Fellow of the Royal Society of Edinburgh and as Commander of the Most Excellent Order of the British Empire (CBE, 2014) is in recognition of his contribution to the development of academic surgery in Edinburgh, specialist liver, pancreatic and biliary surgery as well as surgical education. The distance surgical learning programmes secured the Queen’s Anniversary Prize for Higher and Further Education for the University of Edinburgh in 2013.
Paula Ghaneh – Liverpool, UK
Sean Grimmond – Glasgow, UK
Manuel Hidalgo – Madrid, Spain
Manuel Hidalgo received his MD from the Universidad de Navarra, Pamplona, in 1992 and his PhD from the Universidad Autonoma de Madrid in 1997. He specialised in Medical Oncology at the Hospital Universitario 12 de Octubre, Madrid, obtaining his license in 1996. He completed his training in drug development at the University of Texas Health Science Center, San Antonio (USA), where he briefly joined as Faculty. He then moved to Johns Hopkins University in 2001 as Co-Director of the Drug Development and GI Programmes. He joined the CNIO in 2009 to lead the GI Cancer Clinical Research Unit. Manuel is a founding member of the pancreatic cancer research team – a clinical trials group focusing on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and led the early clinical trials with erlotinib and temsirolimus – two recently approved drugs. Manuel´s work has contributed to the incorporation of molecular endpoints in early clinical trials. His group pioneered the utilisation of personalised xenograft models for drug screening, biomarker development and personalised cancer treatment. He has published more than 180 papers in peer-reviewed journals and his work has been funded by the NCI, AACR, and ASCO. Manuel received an AACR Clinical Research Fellowship and an ASCO Career Development Award for his work on the development of EGFR inhibitors. His most recent efforts focus on novel therapeutics for pancreatic cancer. In 2011, he was named Vice Director of Translational Research at CNIO charged with the mission to foster translational research at CNIO and with a broader implication of the Center in cancer care.
Simon Holligsworth – London, UK
Simon Hollingsworth is group leader in Academic Surgery and Lecturer in Molecular Medicine. His research focuses on the control of gene activity in disease development, and the genetic predisposition to altered physiology (gastrointestinal tract, cancer, and the vascular system). He has wide-ranging expertise in cell and molecular biology, functional assays (tissue explants, immunology and pharmacology), and the development of gene therapy strategies (from laboratory to clinic). Dr Hollingsworth has consulted to a number of Biotechnology and Pharmaceutical Companies, and is an Expert Scientific Advisor to the Gene Therapy Advisory Committee, Department of Health, UK. He has collaborative research with a number of groups within and outside of University College London, and in industry with Johnson & Johnson Pharmaceutical Research & Development, La Jolla, CA.
Claus Jorgensen – Manchester, UK
Rickard Kozarek – Seattle, USA
Dr. Kozarek has been a member of the Section of Gastroenterology at Virginia Mason Medical Center since 1983, serving as Chief of GI for 15 years and currently as the Executive Director of the Digestive Disease Institute, as well as Clinical Professor of Medicine at the University of Washington since 1990. In a career spanning 40 years, Dr. Kozarek has contributed over 500 scientific papers, invited reviews, editorials, and book chapters, and eleven books to the medical literature on topics ranging from therapeutic endoscopy, inflammatory bowel diseases, pancreatic disorders, and practice economics. A past president of the ASGE (American Society of Gastrointestinal Endoscopy), he received its highest honor, the Rudolph Schindler Award in 2005. He is also a past-president of both the World Gastroenterology Organization and the Society for Gastrointestinal Intervention.
Steve Leach – New York, USA
Steven Leach is the David M. Rubenstein Chair and Director of the Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center. He is also Chair of the Pancreatic Cancer Action Network’s Scientific and Medical Advisory Board. Dr. Leach’s lab has a long track record of research productivity in the field of pancreatic tumor biology. His work has been recognized by extensive grant funding in the form of NIH R01, P01 and T32 grants, as well as Columbia University’s 2015 Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research and the 2015 “Nobility in Science Award” from the National Pancreas Foundation.
Anirban Maitra – Houston, USA
A pre-eminent expert in the genetics of pancreatic cancer and the development of targeted therapies for the disease, Dr. Maitra is a Professor of Pathology and Translational Molecular Pathology at University of Texas MD Anderson Cancer Center and Scientific Director of the Sheikh Ahmed Bin Zayed Center for Pancreatic Cancer Research (since August 1, 2013). Prior to this appointment, Dr. Maitra had been at Johns Hopkins University School of Medicine since 2001. In 2004, Dr. Maitra received a Career Development Award from the Pancreatic Cancer Action Network. He is a member of the organization’s Scientific and Medical Advisory Board. Over the past decade, Dr. Maitra’s group has made several seminal observations in the biology and genetics of pancreatic cancer. As a translational researcher, he has a major interest in the early detection of pancreatic cancer.
Lynn Matrisian – Washington, USA
Lynn M. Matrisian, PhD, MBA, is Vice President of Scientific & Medical Affairs at the Pancreatic Cancer Action Network, based in Manhattan Beach CA and Washington DC, USA. She focuses on understanding the scientific and medical activities within the pancreatic cancer field and facilitating these activities through a grants program, a patient support program, and special research initiatives. Dr. Matrisian received her PhD in molecular biology from the University of Arizona, is formerly Professor and founding Chair of the Department of Cancer Biology at Vanderbilt University, and is a fellow of the American Association for Cancer Research Academy.
Colin McKay – Glasgow, UK
Colin McKay has 14 years experience as a consultant surgeon working in a regional referral unit for upper GI and pancreatic disease and more than 20 years experience of research in pancreatic disease. He trained in Glasgow and the West of Scotland and was appointed as Senior Lecturer in Surgery at Glasgow University in 1998. In 1999, he was Associate Professor at the Chinese University of Hong Kong where he trained in endoscopic ultrasound before introducing this technique to the West of Scotland in 2002. Mr McKay has an active research interest with ongoing collaborations within the Beatson Institute for Cancer Research and the University of Glasgow and sits on the management board of the CRUK West of Scotland Cancer Centre. He is involved with a number of ongoing national and international clinical trials. He has published extensively on acute pancreatitis and pancreatic cancer and is a regular invited speaker at national and international meetings. Mr McKay is Lead Clinician for the Scottish HPB Cancer Network, Secretary of UK EUS Users’ and a committee member for the Pancreatic Society of Great Britain and Ireland. He is also a member of the scientific committee of the European Pancreatic Club and a member of the International Association of Pancreatology, the Association of Upper GI Surgeons and the Society for Surgery of the Alimentary Tract.
Somnath Mukherjee – Oxford, UK
Dr Somnath Mukherjee is a Senior Clinical Researcher and Honorary Clinical Oncologist at University of Oxford and Churchill Hospital. His main research interests include chemoradiation for pancreatic and upper gastro-intestinal malignancy. He is the chief investigator of the SCALOP trial, which established the practice of modern pancreatic chemoradiotherapy in the UK. He is also leading the SCALOP2 trial, which is the largest pancreatic chemoradiation trial in the UK, and a co-investigator of other pancreatic chemoradiation studies. He is a member of several national research committees including the NCRI upper GI Clinical Studies Group, the NCRI Pancreatic subgroup and National Radiotherapy research group, CTRAD. He is also currently a member of ASCO guideline writing committee for locally advanced pancreatic cancer.
Owen Sansom – Glasgow, UK
Senior Group Leader at Cancer Research UK Beatson Institute, Glasgow, Professor Sansom is a basic research scientist with an interest in understanding how the common mutations that occur in epithelial cancer provoke tumorigenesis and affect drug response. His group focuses on 2 epithelial cancers: Pancreatic and Colon and uses in vivo models and 3D in vitro models to recapitulate them. Owen has been instrumental in determining the molecular hallmarks of pancreatic and colorectal cancer (CRC). Professor Sansom’s honours and awards include BACR/AstraZeneca Young Scientist Frank Rose Award (2012), CRUK Future Leaders in Cancer Research Prize (2012), Fellow of the Royal Society of Edinburgh (2014).
Aldo Scarpa – Verona, Italy
Professor, Pathology and Molecular Pathology;
Chair, Department of Pathology and Diagnostics; Director, ARC-NET Research Centre for the Applied Research on Cancer, University and Hospital Trust of Verona. Founder of Molecular Diagnostic Laboratories at Verona University-Italy (1985) and Cancer Centre of Cuenca-Ecuador (1999). Leads the Cancer Biobank Network Programme in Veneto Region (Italy) (population 5,000,000). Chief of Diagnostic Molecular Pathology Laboratory recognised by the Italian Government as one of the ten strategic centres in the nation for the development of innovative strategies in molecular medicine. Leader of the Italian effort in the International Cancer Genome Consortium and PI of the National Consortium for early diagnosis of cancer. His research focus is the translation into clinical practice of molecular subclassifications of cancers. He has published over 300 papers.
Kyoichi Takaori – Kyoto, Japan
Dr Kyoichi Takaori is Head, Kyoto University Hospital Pancreas Cancer Unit. His research career has focused on precursor lesions of pancreatic cancer. To promote further research, he is organizing a Japanese registry of familial pancreatic cancer. In addition, he is one of the pioneers in pancreatic surgery, such as a laparoscopic duodenum-preserving pancreatic head resection, robotic artery-first distal pancreatectomy, as well as open artery-first pancreatic resections. His academic career includes Professor of Surgery at Asahi University, Lecturer at Kyoto University and Assistant Professor at Department of Physiology and Biophysics, University of Arkansas for Medical Sciences. For patients with pancreatic cancer, he serves as a member of the Medical Advisory Board for PanCAN Japan and the Scientific Advisory Board for Pancreatic Cancer UK. For the International Association of Pancreatology (IAP), he serves as a Council member. Dr Takaori is the Vice Editor-in-Chief of Pancreatology, the official journal of IAP and EPC.
Margaret Tempero – San Francisco, USA
Dr. Tempero is Director, UCSF Pancreas Center. Her research career has focused on pancreatic ductal adenocarcinoma especially in the area of investigational therapeutics. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Currently her group is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation. She is Chief Emeritus of the Division of Medical Oncology at UCSF and Deputy Director and Director of Research Programs at the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Tempero is a past President of ASCO and recently served on the Oncology Drug Advisory Committee for the FDA. Dr. Tempero is Editor In Chief – JNCCN and Chair – NCCN Pancreas Cancer Guidelines Panel.
William Traverso – Boise, USA
William Traverso, MD is a fellow of the American College of Surgeons. He specializes in pancreatic neoplasms and inflammatory diseases, including pancreatic cancer, islet cell tumors, intraductal papillary mucinous neoplasms (IPMN), cystic neoplasms, and acute and chronic pancreatitis. He has authored or co-authored more than 250 articles on treatment of pancreatic diseases, many of which can be cured for the first time in history.Dr. Traverso serves as the medical director for the Center for Pancreatic and Liver Diseases, St Lukes, Boise, and is director of the Pancreas Club. He is an active member of the North Pacific Surgical Association, Society of the American Gastrointestinal Endoscopic Surgeons, Society for Surgery of the Alimentary Tract, and Seattle and Pacific Coast Surgical Associations. He continues to pursue research in hepatobiliary and pancreatic surgery, acute and chronic pancreatitis, laparoscopic endosurgery, cost and outcome analysis, global databases for continuous quality improvement, and registries to identify familial components of pancreatic disease.
Juan Valle – Manchester, UK
Juan Valle is a Professor of Medical Oncology in the University of Manchester (Institute of Cancer Studies); part of the Manchester Academic Health Sciences Centre (MAHSC). He is based at The Christie NHS Foundation Trust within the Gastrointestinal Disease Group and treats cancers of the pancreas, liver and biliary tract, and neuroendocrine tumours. He is Head of Service for The Christie Neuroendocrine ENETS Centre of Excellence. Professor Valle is a member of the UK National Cancer Research Network (NCRN) Upper Gastrointestinal Clinical Studies Group and member of the hepatobiliary, and pancreatic subgroups; in addition he is Chair of the Neuroendocrine Subgroup. He has been awarded a number of grants for research leading to numerous publications and presentations and national and international meetings and is a peer-reviewer for a number of international medical journals. He is a member of ASCO (American Society of Clinical Oncology), ESMO (European Society of Medical Oncology), UKI NETS (UK and Ireland Neuroendocrine Tumour Society) and ENETS (European Neuroendocrine Tumour Society).
Chris Wolfgang – Baltimore, USA
Christopher L. Wolfgang, M.D., Ph.D., FACS, is an Associate Professor of Surgery at The Johns Hopkins University School of Medicine and an attending surgeon at The Johns Hopkins Hospital. Dr. Wolfgang obtained his medical degree from Temple University School of Medicine and residency training in General Surgery at Penn State Milton S. Hershey Medical Center. In addition, Dr. Wolfgang has obtained a Ph.D. degree in Biochemistry, also from Temple University School of Medicine. Dr. Wolfgang has completed a research fellowship in surgical oncology from Penn State and a clinical fellowship in gastrointestinal surgery at Johns Hopkins. His primary clinical interests are cancers and benign disease of the liver, pancreas, bile duct and gallbladder. His major scientific interest is in the biological behavior of pancreatic cancers.